Project Grant R61NS146312
- Federal Project Grant Award Summary The University of Florida's Division of Sponsored Research received a $423,750 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded March 16, 2026, with completion targeted for February 28, 2031. This research initiative focuses on identifying approved drugs capable of increasing Brain-Derived Neurotrophic...
- Federal Project Grant Award Summary The University of Florida's Division of Sponsored Research received a $422,125 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 15, 2025, with a completion date of July 31, 2027. The research focuses on characterizing the role of the DNAJC12 protein in dopamine biosynthesis and physiology through the...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $114,102 to the University of Florida's Division of Sponsored Research on May 4, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This two-year Project Grant, concluding April 30, 2028, supports translational neuroscience research investigating the role of striatal mu opioid receptor-containing neurons in L-DOPA-induced...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This exploratory research project, scheduled for completion by May 31, 2027, investigates the roles of the deubiquitylation pathway in TDP-43 (TAR DNA-binding protein 43) pathology relevant to...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Miami $599,005 on August 21, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support a five-year research project extending through July 31, 2030. The award funds mechanistic research investigating the role of NFKBIA (IκBα) deficiency in glioma development, with particular focus on how NFKBIA...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of South Florida a $608,679 Project Grant effective August 1, 2025, through July 31, 2030, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating the mechanisms of claudin-5 regulation during neuroinflammation, specifically examining the roles of transcription factors FOXO1 and...
- Federal Project Grant Award Summary Anekabio LLC, in partnership with the University of Florida, received a $908,874 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on September 23, 2025. The award supports the development and validation of efficacy biomarkers for QTE Therapy, an innovative multi-targeted treatment for Friedreich's Ataxia...
- Federal Project Grant Award Summary The San Diego Biomedical Research Institute received a $541,750 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 15, 2026, with completion targeted for April 30, 2028. This research project focuses on discovering novel noncanonical autophagy modulators to address protein aggregation and neuronal...
- Federal Project Grant Award Summary The University of Georgia Research Foundation, Inc., received a $1.297 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on May 8, 2026, with a completion date of April 30, 2029. This research initiative investigates neuroinflammatory epitranscriptomic mechanisms in Parkinson's disease,...
- Federal Project Grant Award Summary New York Medical College received a $396,804 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective August 1, 2025 through July 31, 2026. The award supports research to develop and characterize a preclinical animal model of Lennox-Gastaut Syndrome (LGS), a severe developmental epileptic encephalopathy...
The University of Florida's Division of Sponsored Research received a $420,990 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 1, 2026 through April 30, 2027. This award supports the development of an advanced brain-penetrant enzyme therapy designed to treat Lafora Disease (LD), a fatal autosomal recessive neurodegenerative disorder characterized by seizures, myoclonus, and rapid cognitive decline. The research combines two novel technologies: an antibody-enzyme fusion (AEF) therapy that degrades pathogenic polyglucosan bodies in the brain with a transferrin receptor (TFR)-targeting brain shuttle platform that enables systemic drug administration and robust blood-brain barrier penetration. The funded research will deliver a humanized brain-penetrant BBB-AEF (blood-brain barrier antibody-enzyme fusion) therapeutic capable of crossing the blood-brain barrier, penetrating brain parenchyma, accessing the cytoplasm, and degrading disease-causing polyglucosan bodies. To support this translational research, investigators will establish a humanized TFR knock-in Lafora Disease mouse model (HTFR-LKO) and develop necessary assays to assess therapeutic target engagement. These deliverables advance clinical translation of the combined BBB-AEF technology through proof-of-concept validation in preclinical models, positioning the therapeutic approach for potential future clinical development in treating this currently incurable neurological disease.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $421.0k | 5/4/26 |